Secchi Teresa, Baselli Lucia Augusta, Russo Maria Chiara, Borzani Irene Maria, Carta Federica, Lopopolo Maria Amalia, Foà Michaela, La Vecchia Adriano, Agostoni Carlo, Agosti Massimo, Dellepiane Rosa Maria
University of Milan, Milan, Italy.
Pediatric Intermediate Care Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
Front Pediatr. 2022 May 17;10:773751. doi: 10.3389/fped.2022.773751. eCollection 2022.
In primary antibody deficiencies (PADs), pulmonary complications are the main cause of morbidity, despite immunoglobulin substitutive therapy, antibiotic treatment of exacerbations, and respiratory physiotherapy. Current Italian recommendations for surveillance of PADs respiratory complications include an annual assessment of spirometry and execution of chest high-resolution computed tomography (HRCT) every 4 years.
This study aimed to evaluate the effectiveness of the lung clearance index (LCI) as an early marker of lung damage in patients with PADs. LCI is measured by multiple breath washout (MBW), a non-invasive and highly specific test widely used in patients with cystic fibrosis (CF).
Pediatric patients with PADs ( = 17, 10 male, 7 female, and age range 5-15 years) underwent baseline assessment of lung involvement with chest HRCT, spirometry, and multiple breath nitrogen washout. Among them, 13 patients were followed up to repeat HRCT after 4 years, while performing pulmonary function tests annually. Their baseline and follow-up LCI and forced expiratory volume at 1 s (FEV1) values were compared, taking HRCT as the gold standard, using logistic regression analysis.
Lung clearance index [odds ratio (OR) 2.3 (confidence interval (CI) 0.1-52) at baseline, OR 3.9 (CI 0.2-191) at follow-up] has a stronger discriminating power between altered and normal HRCT rather than FEV1 [OR 0.6 (CI 0.2-2) at baseline, OR 1.6 (CI 0.1-13.6) at follow-up].
Within the context of a limited sample size, LCI seems to be more predictive of HRCT alterations than FEV1 and more sensitive than HRCT in detecting non-uniform ventilation in the absence of bronchiectasis. A study of a larger cohort of pediatric patients followed longitudinally in adulthood is needed to challenge these findings.
在原发性抗体缺陷(PAD)中,尽管进行了免疫球蛋白替代治疗、对病情加重进行抗生素治疗以及呼吸物理治疗,但肺部并发症仍是发病的主要原因。意大利目前关于PAD呼吸并发症监测的建议包括每年进行一次肺活量测定评估,并每4年进行一次胸部高分辨率计算机断层扫描(HRCT)。
本研究旨在评估肺清除指数(LCI)作为PAD患者肺损伤早期标志物的有效性。LCI通过多次呼气洗脱(MBW)测量,这是一种广泛应用于囊性纤维化(CF)患者的非侵入性且高度特异性的检测方法。
对患有PAD的儿科患者(n = 17,10名男性,7名女性,年龄范围5 - 15岁)进行胸部HRCT、肺活量测定和多次呼气氮洗脱以评估肺部受累情况的基线评估。其中,13名患者在4年后进行随访以重复HRCT,同时每年进行肺功能测试。以HRCT作为金标准,采用逻辑回归分析比较他们的基线和随访时的LCI以及第1秒用力呼气量(FEV1)值。
肺清除指数[基线时比值比(OR)为2.3(置信区间(CI)为0.1 - 52),随访时OR为3.9(CI为0.2 - 191)]在区分HRCT改变和正常方面比FEV1具有更强的鉴别能力[基线时OR为0.6(CI为0.2 - 2),随访时OR为1.6(CI为0.1 - 13.6)]。
在样本量有限的情况下,LCI似乎比FEV1更能预测HRCT改变,并且在检测无支气管扩张情况下的不均匀通气方面比HRCT更敏感。需要对更大队列的儿科患者进行成年后的纵向随访研究以验证这些发现。